« Return to News | Technology Solutions

Genexion selects goBalto's Tracker platform

Thursday, November 17, 2011 02:59 PM

SanFrancisco-based goBalto has entered a strategic partnership with Genexion, a CRO that has selected Tracker, goBalto's web-based clinical trials platform, for its clinical research study start-up and monitoring.

"Interest in Tracker has been strong, and we expect to announce some significant partnerships in the near future to help drive industry-wide acceptance of this technology," said Jae Chung, founder and CEO of goBalto.

Tracker, launched in June 2011, is the first purpose-built Software-as-a-Service clinical research tool that enables clinical trials sponsors and CROs to collaborate with multiple partners directly from the web in a transparent and regulatory compliant manner.

"A good start-up is key to the success of any clinical trial. With Tracker, we are now in full control of this critical phase," said Dr. Yves Grumser, CEO of Genexion. "With fewer resources, we can now identify potential start-up gaps earlier, focus on sites that need more support, share up-to-date information among all stakeholders and report accurate and up-to-date project tracking information to our clients. Tracker has changed the way we are managing trials."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.